Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) and Aprea Therapeutics (NASDAQ:APRE – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, risk and valuation.
Profitability
This table compares Unicycive Therapeutics and Aprea Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Unicycive Therapeutics | N/A | N/A | -34.98% |
Aprea Therapeutics | -1,012.37% | -56.38% | -46.35% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Unicycive Therapeutics and Aprea Therapeutics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Unicycive Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
Aprea Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Institutional & Insider Ownership
40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 24.1% of Unicycive Therapeutics shares are held by insiders. Comparatively, 12.8% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Unicycive Therapeutics has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.
Earnings and Valuation
This table compares Unicycive Therapeutics and Aprea Therapeutics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Unicycive Therapeutics | $680,000.00 | 25.44 | -$30.54 million | ($1.19) | -0.39 |
Aprea Therapeutics | $580,000.00 | 29.30 | -$14.29 million | ($3.32) | -0.94 |
Aprea Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Unicycive Therapeutics beats Aprea Therapeutics on 13 of the 15 factors compared between the two stocks.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.